| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Kymera Therapeutics, Inc. | Chief Business Officer | Common Stock | 59,306 | $4,982,926 | $84.02 | 02 Mar 2026 | Direct |
| Kymera Therapeutics, Inc. | Chief Business Officer | Stock Option (Right to Buy) | 18,450 | 02 Mar 2026 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| KYMR | Kymera Therapeutics, Inc. | 02 Mar 2026 | 2 | $0 | 4 | Chief Business Officer | 04 Mar 2026, 18:00 |
| KYMR | Kymera Therapeutics, Inc. | 08 Apr 2025 | 2 | $0 | 4 | Chief Business Officer | 09 Apr 2025, 08:05 |
| KYMR | Kymera Therapeutics, Inc. | 08 Apr 2025 | 0 | $0 | 3 | Chief Business Officer | 09 Apr 2025, 08:00 |